(Press-News.org) JACKSONVILLE, Fla. -- In their bid to find the best combination of therapies to treat anaplastic thyroid cancer (ATC), researchers on Mayo Clinic's Florida campus demonstrated that all histone deacetylase (HDAC) inhibitors are not created equal.
In testing multiple HDAC inhibitors in combination with the chemotherapy drug paclitaxel, known to give some benefit for this aggressive cancer, they found that class II HDAC inhibitors signal through a newly discovered pathway to promote synergy with chemotherapy treatment.
They say their study, published online today in Endocrine Related Cancers, provides some surprising findings about HDAC inhibitors, which all seemingly do the same thing -- remove the HDAC enzymes that wrap DNA so tightly that genes are silenced. There are 11 known HDACs. Blocking HDAC allows the genes to unwind, opening up like a toy Slinky to become active.
"Physicians and researchers should know that just using any of the many approved HDAC inhibitors for a patient's cancer may not offer the results one wants to see," says co-author Robert Smallridge, M.D., an endocrinologist who treats thyroid cancer. "That appears to be the case in ATC, and it is probably likely true in a number of cancers."
The Mayo team has long sought to understand ATC at a molecular level to find treatments that offer longer survival.
"Although ATC is rare - accounting for only 1-2 percent of thyroid cancers, it is responsible for up to 50 percent of thyroid cancer deaths," says John Copland, Ph.D., a cancer biologist and the study's senior author.
The mortality rate for ATC nears 100 percent. Diagnosis to death can be measured in weeks to months. When ATC is found early, it is treated aggressively, and patients can survive for a number of years.
"I doubt a single drug will ever work in this cancer, so it is a matter of finding which drugs in combination are going to be most effective," says Dr. Smallridge.
Even as he leads a national clinical trial testing a combination of paclitaxel chemotherapy with an experimental agent known as efatutazone, Dr. Smallridge is working with Dr. Copland and researcher Laura Marlow to find an HDAC inhibitor that might offer additional benefit.
HDAC inhibitors have been approved for use in blood cancers and are being tested for benefit in other cancers, such as breast, colorectal, gastric, liver, lung and prostate cancers that overexpress specific HDAC proteins.
"HDAC inhibitors can increase activity of RhoB, a tumor suppressor that we had discovered earlier, that is switched off in ATC," says Dr. Copland. "We also know that this RhoB pathway, once turned on, can stimulate the expression of two proteins: p21, which prevents cells from replicating, and BIM, which induces cell death -- both of which can help stop cancer growth."
Marlow, the laboratory manager in Dr. Copland's lab, led the study by testing whether different HDAC drugs work with paclitaxel to turn on RhoB, and what effect they had on p21 and BIM.
Marlow found that only HDAC inhibitors that increase expression of BIM work with paclitaxel. And, there were two agents in their study that did that: vorinostat and belinostat. Both are class II HDAC inhibitors. She discovered that HDAC6 is specifically suppressed leading to an increase in RhoB, and BIM is preferentially expressed due to RhoB's re-expression. They also showed that HDAC6 is overexpressed in patient ATC tissues, indicating that class II HDAC inhibitors will be effective in patients.
She also found that class I HDAC inhibitors suppress HDAC1, which mostly upregulates p21 and sometimes BIM, but to a lesser degree. When p21 is produced, no synergy occurs with paclitaxel; therefore, there is no benefit of adding the HDAC inhibitor to treatment.
"Only vorinostat and belinostat always induced the BIM protein, always induced cell death, and always showed synergy with paclitaxel," Marlow says.
That suggests that patient ATC biopsies should be examined before an HDAC inhibitor is used with chemotherapy to see whether p21 or BIM protein are being produced in the tumor during treatment, Dr. Smallridge says. Thus, BIM upregulation and protein expression should predict a response to therapy and synergy of the two drugs, he says.
Dr. Copland says that the study shows that molecular work decoding cancer signaling pathways and the effect of agents on those pathways is possible -- and necessary. "We now know which of the many HDAC inhibitors to try with ATC," he says. "It makes sense that similar investigations would help other researchers who want to use an HDAC inhibitor to treat specific cancers."
INFORMATION:
Ilah Bok, a technician in Dr. Copland's lab, also contributed to the research.
This work was supported by the National Institute of Health and Medical Research (R01CA136665); the Florida Department of Health Bankhead-Coley Cancer Research Program (FL09B202); Alfred D. and Audrey M. Petersen; the Francis and Miranda Childress Foundation Fund for Cancer Research; John A. and Bette B. Klacsmann Fund for Cancer Research on Mayo Clinic's Florida campus; and the Betty G. Castigliano Fund in Cancer Research Honoring S. Gordon Castigliano, M.D., cancer research on the Florida campus.
About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to medical research and education, and providing expert, whole-person care to everyone who needs healing. For more information, visit mayoclinic.com or newsnetwork.mayoclinic.org.
MEDIA CONTACT: Kevin Punsky, Mayo Clinic Public Affairs, 904-953-0746, punsky.kevin@mayo.edu
WASHINGTON, July 23, 2015 -- Have you ever wished you could hide under an invisibility cloak like Harry Potter or conceal your car with a Klingon cloaking device like in Star Trek? In a special Thursday bonus episode of Reactions, we celebrate the International Year of Light by exploring the science behind light, sight and invisibility. Though we can't make ourselves invisible yet, some promising research may light the way - or rather, bend the light away. Check it out here: https://youtu.be/sN70Bgm_PAQ.
This episode of Reactions was produced in collaboration with the ...
HANOVER, N.H. - Potentially destructive high-energy electrons streak into Earth's atmosphere from space, not as Shakespeare's "gentle rain from heaven," but at velocities approaching the speed of light.
This particle onslaught can lead to ozone depletion and damage to the orbital satellites that provide us with the navigation, communication, weather, and military-recognizance information upon which we have become increasingly dependent. These satellites fly through the Van Allen radiation belts -- giant concentric layers of charged particles held in place by the Earth's ...
A new guideline for the nutrition of management gastrointestinal symptoms in children with autism spectrum disorders (ASD) provides a framework for clinicians to navigate frequently seen issues such as food selectivity, alternative diets and nutritional deficits. The expert panel was convened at Marcus Autism Center, an affiliate of Children's Healthcare of Atlanta and the resulting guideline was published online by the Journal of the Academy of Nutrition and Dietetics (JAND).
"Children with autism are at increased risk for feeding and gastrointestinal (GI) concerns compared ...
PROVIDENCE, R.I. [Brown University] -- Brown University computer scientists have developed a new interactive tool to help researchers and clinicians explore the genetic underpinnings of cancer.
The tool -- dubbed MAGI, for Mutation Annotation and Genome Interpretation -- is an open-source web application that enables users to search, visualize, and annotate large public cancer genetics datasets, including data from The Cancer Genome Atlas (TCGA) project.
"The main motivation for MAGI has been to reduce the computational burden required for researchers or doctors to ...
How much does diet affect the cancer patient? Do "antioxidants" really play an important role in health - or are they causing more cancers than they cure? And what exactly is the relationship between obesity and cancer?
The latest Special Issue in ecancermedicalscience collects four original articles from experts in cancer and metabolism, addressing the hottest areas of research in this rapidly developing field.
"In our clinical practice, cancer patients often ask 'Doctor, is there something specific I should eat or avoid eating?'" says Guest Editor of this Special ...
The brain's effect on other parts of the body has been well established. Now, a group that includes two University of Florida Health researchers has found that it's a two-way street: Body fat can send a signal that affects the way the brain deals with stress and metabolism.
While the exact nature of those signals remains a mystery, researchers say simply knowing such a pathway exists and learning more about it could help break a vicious cycle: Stress causes a desire to eat more, which can lead to obesity. And too much extra fat can impair the body's ability to send a ...
Many of the same genes may affect GCSE results across a broad range of subjects according to a new study from the Institute of Psychiatry, Psychology & Neuroscience at King's College London.
The research, published today in Scientific Reports, also suggests that educational achievement at GCSE is highly heritable, with over half of the difference between results potentially due to inherited differences in DNA.
Previous studies have shown that academic achievement in the core subjects of English, mathematics and science at GCSE may be influenced by the same genetic traits. ...
Philadelphia, PA, July 23, 2015 - Posttraumatic stress disorder (PTSD) and traumatic brain injury (TBI) can have devastating consequences. Both are associated with high rates of disability and suicide, and although they are separate conditions, they commonly co-occur. For example, a soldier who has developed PTSD as a result of a traumatic experience may have also sustained a brain injury during that experience.
Significant research has been conducted to understand the brain mechanisms underlying PTSD and TBI, but there has still been a lack of knowledge regarding exactly ...
New research by health scientists at the University of York has revealed that a greater proportion of men than women suffer from cannabis psychosis.
There has been much research exploring the nature of the relationship between cannabis -- the most widely used illicit drug in the United Kingdom -- and psychosis, however the role of gender in relation to cannabis psychosis is less well explored and understood.
A new study by researchers in the Department of Health Sciences at York used large datasets over a period of 11 years to investigate the differences in men and ...
A new drug that blocks cancer's escape route from chemotherapy could be used to treat deadly lung and pancreatic cancers, new research reports.
Scientists have shown in human cancer cells and in mice that the drug - discovered at The Institute of Cancer Research, London - boosts the effectiveness of conventional chemotherapy.
The drug, known as CCT245737, is scheduled to begin first-in-human clinical trials in patients with lung and pancreatic cancers - two cancers with low survival rates that continue to resist currently available treatments.
The new study is published ...
